The Liver Cancer Program (LCP) conducts clinical trials for patients with many different types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.
Liver Cancer Program
A multidisciplinary network of researchers and clinicians dedicated to improving early detection, diagnosis, prognosis and treatment of liver cancer.
New Discoveries
Learn about our most recently published research.
Seminar Series
Daniela Sia, Ph.D., Associate Professor, Mount Sinai, New York, "Discovery of Novel Therapeutic Vulnerabilities in Cholangiocarcinoma," Thursday, Sept. 25, 2025, 1 p.m. EST
Liver Cancer Program
About
The mission of the NCI-CCR-LCP is to develop a multi-disciplinary program focused on the prevention, early detection, improved diagnosis and treatment of liver cancer. Liver cancer is the 4th most common cause of cancer-related death worldwide.
In the United States, liver cancer is the 6th most common cause of cancer-related death and is one of the few cancers with rising incidence and mortality, with 42,240 new cases of liver cancer diagnosed per year. Liver cancer remains a difficult-to treat disease with sub-optimal patient diagnosis and poor patient survival mainly due to the lack of screening tools, advanced stage of tumors at diagnosis, and the lack of approved novel therapies.
To address these dire concerns, the NCI-CCR-LCP will consolidate expertise and create an interactive and collaborative environment to foster liver cancer care and research through innovative laboratory studies and promising clinical applications, such as molecular subgrouping of patients and biomarker-guided molecularly-targeted therapies.
Our multidisciplinary research and clinical team will apply a transdisciplinary approach with integration of research and clinical expertise to improve the diagnosis, prognosis, treatment and outcome of patients with liver disease and cancer.
Researchers
One of the central aims of the NCI-CCR-LCP is to foster collaborations between intramural and extramural investigators with an interest in liver cancer research. We plan to initiate and support these collaborations at every level.
Team
Leadership
CCR Team
Program Staff
Team Members and Advisory Board
Our team members include clinical, basic, and translational researchers from the Center for Cancer Research (CCR), the Division of Cancer Epidemiology and Genetics (DCEG), and the Center for Global Health at the National Cancer Institute (NCI); the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the NIH Clinical Center.
Our Advisory Board members are from the extramural cancer research community.
News
Seminars
All seminars are virtual.
Visit our archives page to learn more about seminars from previous years.
Recorded seminars are available below and on our YouTube Playlist as part of NCI YouTube.
2025
Fall 2025
September 25 Daniela Sia,PhD, Associate Professor, Mount Sinai, New York (1pm EST)
"Discovery of Novel Therapeutic Vulnerabilities in Cholangiocarcinoma"
Join by WebEx: https://cbiit.webex.com/cbiit/j.php?MTID=m7cf0ce55f59544c83d7fd43548aaa84a
Meeting number: 2302 816 8043
Meeting password: 7K7eEY7YWR*
Previous Seminars
Spring 2025
Cancelled: May 15 Juan Valle, MD, Chief Medical Officer, Cholangiocarcinoma Foundation (10am EST)
Cancelled: March 6 Daniela Sia,PhD, Assistant Professor, Mount Sinai, New York (1pm EST)
"Discovery of Novel Therapeutic Vulnerabilities in Cholangiocarcinoma"
Cancelled: January 27 Praveen Sethupathy, PhD, Chair and Professor, Center for Vertebrate Genomics, Cornell University (9am EST)
"Single-Cell Analysis of Fibrolamellar Carcinoma Reveals Unique Vulnerabilities"
2024 Seminars
December 12 Julien Calderaro, MD, PhD, Associate Professor, Henri Mondor University Hospital, France (9am EST)
September 12 Ghassan Abou Alfa, MD, Professor, Memorial Sloan Kettering Cancer Center (1pm EST)
May 16 Hien Dang, PhD, Assistant Professor and Vice Chair, Thomas Jefferson University (1pm EST)
March 18 Valerie Chew, PhD, Assistant Professor, SingHealth Duke-NUS
February 26 Amit Singal, MD, Professor, UT Southwestern
January 29 Lopa Mishra, MD, Professor and Chair, Feinstein Institute for Medical Research and Cold Spring Harbor Laboratory
2023 Seminars
December 14 Scott Friedman, MD, Professor and Chief, Mount Sinai, New York
November 13 Giorgio Trinchieri, MD, Senior Investigator and Chief, Laboratory of Integrative Cancer Immunology, NCI, NIH
October 19 Irene Ng, MD, PhD, Chair and Professor, The University of Hong Kong
September 21 Mitesh Borad, MD, Professor, Mayo Clinic
June 12 Anna Mae Diehl, MD, Professor, Duke University
May 18 David Brenner, MD, President and Chief Executive Officer of Medicine, Sanford Burnham Prebys, San Diego (La Jolla), CA
Liver Fibrosis and Hepatocellular Carcinoma
March 30 Stephanie Ma, PhD, Associate Professor, The University of Hong Kong
February 23 Hashem B. El-Serag, MD, MPH, Professor, Baylor College of Medicine
January 12 Anna Suk-Fong Lok, MD, Assistant Dean, University of Michigan Medical School
Contact
For questions about patient care or clinical trials
Please contact Donna Mabry, MS, CRNP
240-858-3155 | donna.mabry@nih.gov
For questions about our research program
Please contact Anuradha S. Budhu, Ph.D.
240-760-6837 | budhua@mail.nih.gov